First, the real translational potential of Nrf2 activation in ALS remains uncertain, as most supporting evidence derives from preclinical or short-term models, with limited validation in large, genetically diverse patient cohorts. The gene discussed is NFE2L2; the disease is amyotrophic lateral sclerosis.